drugset / Trial / NCT02999893

A Study of APR-246 in Oesophageal Cancer

NCT02999893

Phase 1/2 Terminated 5 enrolled Peter MacCallum Cancer Centre, Australia
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether APR-246, 5-FU and cisplatin are safe and effective in the treatment of platinum resistant oesophageal cancer.

Timeline

Start
2017-04-11
Primary completion
2020-10-16
Completion
2021-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject eprenetapopt Small molecule 50 mg/kg Intravenous
Subject eprenetapopt Small molecule 75 mg/kg Intravenous
Subject eprenetapopt Small molecule 100 mg/kg Intravenous